Seuraa
Michele Simbolo
Michele Simbolo
University of Verona
Vahvistettu sähköpostiosoite verkkotunnuksessa univr.it
Nimike
Viittaukset
Viittaukset
Vuosi
Pan-cancer analysis of whole genomes
Nature 578 (7793), 82-93, 2020
2081*2020
Whole-genome landscape of pancreatic neuroendocrine tumours
A Scarpa, DK Chang, K Nones, V Corbo, AM Patch, P Bailey, RT Lawlor, ...
Nature 543 (7643), 65-71, 2017
9432017
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
Y Jiao, TM Pawlik, RA Anders, FM Selaru, MM Streppel, DJ Lucas, ...
Nature genetics 45 (12), 1470-1473, 2013
7302013
Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations
CP Wardell, M Fujita, T Yamada, M Simbolo, M Fassan, R Karlic, P Polak, ...
Journal of hepatology 68 (5), 959-969, 2018
3512018
DNA qualification workflow for next generation sequencing of histopathological samples
M Simbolo, M Gottardi, V Corbo, M Fassan, A Mafficini, G Malpeli, ...
PloS one 8 (6), e62692, 2013
3422013
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups
M Simbolo, M Fassan, A Ruzzenente, A Mafficini, LD Wood, V Corbo, ...
Oncotarget 5 (9), 2839, 2014
2272014
Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin‐remodelling genes as major players and a prognostic role for …
M Simbolo, A Mafficini, KO Sikora, M Fassan, S Barbi, V Corbo, ...
The Journal of pathology 241 (4), 488-500, 2017
2122017
A cross-species analysis in pancreatic neuroendocrine tumors reveals molecular subtypes with distinctive clinical, metastatic, developmental, and metabolic characteristics
A Sadanandam, S Wullschleger, CA Lyssiotis, C Grötzinger, S Barbi, ...
Cancer discovery 5 (12), 1296-1313, 2015
1772015
MIR21 drives resistance to heat shock protein 90 inhibition in cholangiocarcinoma
A Lampis, P Carotenuto, G Vlachogiannis, L Cascione, S Hedayat, ...
Gastroenterology 154 (4), 1066-1079. e5, 2018
1232018
Cholangiocarcinoma heterogeneity revealed by multigene mutational profiling: clinical and prognostic relevance in surgically resected patients
A Ruzzenente, M Fassan, S Conci, M Simbolo, RT Lawlor, C Pedrazzani, ...
Annals of surgical oncology 23, 1699-1707, 2016
1082016
Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations
M Simbolo, S Barbi, M Fassan, A Mafficini, G Ali, C Vicentini, N Sperandio, ...
Journal of Thoracic Oncology 14 (9), 1651-1661, 2019
1012019
BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing
A Mafficini, M Simbolo, A Parisi, B Rusev, C Luchini, I Cataldo, E Piazzola, ...
Oncotarget 7 (2), 1076, 2016
992016
Metformin enhances cisplatin-induced apoptosis and prevents resistance to cisplatin in co-mutated KRAS/LKB1 NSCLC
M Moro, E Caiola, M Ganzinelli, E Zulato, E Rulli, M Marabese, ...
Journal of Thoracic Oncology 13 (11), 1692-1704, 2018
962018
High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas
M Simbolo, C Mian, S Barollo, M Fassan, A Mafficini, D Neves, ...
Virchows archiv 465, 73-78, 2014
822014
Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm
G Pelosi, F Bianchi, E Dama, M Simbolo, A Mafficini, A Sonzogni, S Pilotto, ...
Virchows Archiv 472, 567-577, 2018
742018
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers
M Fassan, M Simbolo, E Bria, A Mafficini, S Pilotto, P Capelli, ...
Gastric cancer 17, 442-449, 2014
742014
Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex
A Gkountakos, S Pilotto, A Mafficini, C Vicentini, M Simbolo, M Milella, ...
Carcinogenesis 39 (8), 971-980, 2018
722018
Pembrolizumab activity in recurrent high-grade gliomas with partial or complete loss of mismatch repair protein expression: a monocentric, observational and prospective pilot study
G Lombardi, V Barresi, S Indraccolo, M Simbolo, M Fassan, ...
Cancers 12 (8), 2283, 2020
622020
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer
M Milella, I Falcone, F Conciatori, S Matteoni, A Sacconi, T De Luca, ...
Scientific reports 7 (1), 43013, 2017
582017
Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine
M Simbolo, C Vicentini, A Mafficini, M Fassan, S Pedron, V Corbo, ...
Virchows Archiv 473, 709-717, 2018
572018
Järjestelmä ei voi suorittaa toimenpidettä nyt. Yritä myöhemmin uudelleen.
Artikkelit 1–20